Validated HPLC-MS-MS method for simultaneous determination of atorvastatin and 2-hydroxyatorvastatin in human plasma -: pharmacokinetic study

被引:60
作者
Borek-Dohalsky, V.
Huclova, J.
Barrett, B.
Nemec, B.
Ulc, I.
Jelinek, I.
机构
[1] CEPHA Sro Plzen, Bioanalyt Lab, Plz 32300, Czech Republic
[2] Charles Univ, Dept Analyt Chem, Prague 12843 2, Czech Republic
关键词
atorvastatin; HPLC; MS; plasma; pharmacokinetic study;
D O I
10.1007/s00216-006-0655-3
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Cholesterol-reducing statin drugs are the most frequently prescribed agents for reducing morbidity and mortality related to coronary heart disease. In this publication a validated, highly sensitive, and selective isocratic HPLC method is reported for quantitative determination of the major statin drug atorvastatin (ATV) and its metabolite 2-hydroxyatorvastatin (HATV). Detection was performed with an electrospray ionization triple-quadrupole mass spectrometer equipped with an ESI interface operating in positive-ionization mode. Multiple reaction monitoring (MRM) was used for MS-MS detection. The calibration plot was linear in the concentration range 0.10-40.00 ng mL(-1) for both ATV and HATV. Inter-day and intra-day precision and accuracy of the proposed method were characterized by measurement of relative standard deviation (RSD) and percentage deviation, respectively; both were less than 8% for both analytes. The limit of quantitation was 0.02 ng mL(-1) for ATV and 0.07 ng mL(-1) for HATV. The method was used for pharmacokinetic study of ATV and HATV. Pharmacokinetic data for all analytes are also reported.
引用
收藏
页码:275 / 285
页数:11
相关论文
共 14 条
[1]   Development and validation of a high-performance liquid chromatography tandem mass spectrometry assay for atorvastatin, ortho-hydroxy atorvastatin, and para-hydroxy atorvastatin in human, dog, and rat plasma [J].
Bullen, WW ;
Miller, RA ;
Hayes, RN .
JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY, 1999, 10 (01) :55-66
[2]   Development of electrochemical methods for determination of atorvastatin and analytical application to pharmaceutical products and spiked human plasma [J].
Erk, N .
CRITICAL REVIEWS IN ANALYTICAL CHEMISTRY, 2004, 34 (01) :1-7
[3]   An HPLC method for the determination of atorvastatin and its impurities in bulk drug and tablets [J].
Ertürk, S ;
Aktas, ES ;
Ersoy, L ;
Fiçicioglu, S .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2003, 33 (05) :1017-1023
[4]  
Jemal M, 1999, RAPID COMMUN MASS SP, V13, P1003, DOI 10.1002/(SICI)1097-0231(19990615)13:11<1003::AID-RCM597>3.0.CO
[5]  
2-L
[6]   Effect of itraconazole on the pharmacokinetics of atorvastatin [J].
Kantola, T ;
Kivistö, KT ;
Neuvonen, PJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (01) :58-65
[7]   Atorvastatin - A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias [J].
Lea, AP ;
McTavish, D .
DRUGS, 1997, 53 (05) :828-847
[8]   Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin [J].
Lilja, JJ ;
Kivistö, KT ;
Neuvonen, PJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 66 (02) :118-127
[9]   Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects [J].
Posvar, EL ;
Radulovic, LL ;
Cilla, DD ;
Whitfield, LR ;
Sedman, AJ .
JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 36 (08) :728-731
[10]   EFFECT OF FOOD ON THE BIOAVAILABILITY OF ATORVASTATIN, AN HMG-COA REDUCTASE INHIBITOR [J].
RADULOVIC, LL ;
CILLA, DD ;
POSVAR, EL ;
SEDMAN, AJ ;
WHITFIELD, LR .
JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 35 (10) :990-994